Interferons Flashcards
3 distinct classes of interferon
- IFN-α
- IFN-β
- IFN-γ
Interferon
A substance secreted by virally infected cells that mediate resistance
Functions of interferons
- Induction of cellular resistance to viral attack
- Regulation of immune function
- Regulation of growth and differentiation of many cell types
- Sustenancce of early phases of pregnancy in some animal species
Type I interferons
- Acid-stable
IFN-α & IFN-β
- 30% amino aicd identity
- bind to same receptor
- induce similar activities
Type II interferon
IFN-γ
- evolutionarily distinct from other interferons
- binds to separate receptor
- induces different range of activity
Biological effects of type I interferons
Antiviral activity
Anti-proliferative effect
Anti-tumour effects of type I interferons
Have ability to increase NK and T-cytotoxic cell acitivity
Biological effects of type II interferons
Weak antiviral and anti-proliferative activity.
Represents main macrophage-activating factor
IFN-γ
Macrophage-mediated effects
- Destruction of invading microbes
- Destruction of intracellular pathogens
- Tumour toxicity
- Increased MHC antigen expression leading to enhanced activation of lymphocytes via antigen presentation
IFN-γ
What happens when IFN-γ is co-administered with type I interferons
Potentiates the antiviral and anti-proliferation activities of IFN-α & IFN-β
Initial therapeutic application of interferons
- Identified in late 1950s but therapeutic application rendered impractical due to low levels produced by the body.
- Large scale purification from sources like blood was non viable.
- Interferons exhibit species preference - only human derived interferons can be used in human medicine
First production of interferon in small quantities
- Until 1970s
- Sourced from human leukocytes obtained from transfused blood supplies
- only 1% pure
- contained mixture of various IFN-αs
First production of interferon in large quantities
- late 1970s
- mammalian cell culture
- cancer cell lines were found to secrete greater quantities of interferons and were amenable to large scale culture due to their transformed nature
Namalaw cell line
A specific strain of human lymphoblastoid cells
- the major industrial source of interferon
Interferon production from namalwa cell line
- Cells propagated in animal cell fermenters
- The additon of an inducing virus (sendai virus)
- Results in production of leukocyte interferon.
- Final product contained 9 IFN-α subtypes
Tradename given to one of first approved interferon products
Wellferon
Most interferons currently in medical use
Recombinant human products produced by E. coli
Clinical Studies of IFN-α
- Conducted in the late 1970s
- Found that IFN-α could induce regression of tumors in breast cancer, certain lymphomas, and multiple myeloma.
- Could also delay the recurrence of tumor growth after surgery in patients with osteogenic sarcoma.
First recombinant interferon to become available for clinical studies
IFN-α2a (Intron A)
In 1980
Schering Plough’s rhIFN-α2b (Intron A)
First approved in 1986 in US for hairy celll leukaemia - now 50+ countries
Now approved in the US for hepatitis B and C
What is the producer microbe for Intron A and where is it expressed?
- E. coli.
- Expressed intracellularly and harbors a cytoplasmic expression vector (KMAC-43) containing the interferon gene.
Where are the manufacturing facilities for Intron A located and how is the processing undertaken?
- New Jersey and in Brinny, Co. Cork.
1. The upstream processing (fermentation) and downstream processing (purification and formulation) are physically separated, being undertaken in separate buildings.
2. Fermentation is undertaken in 42,000L stainless steel vessels.
3. After recovery, a number of chromatographic purification steps are undertaken within a large cold-room adapted to function under cleanroom conditions.
4. Crystallization of the IFN-α2b is then undertaken as a final purification step.
Modified recombinant IFN-αs
PEGlyated interferons
- PEG Intron A
- ViraferonPeg
Sythetic interferons
- Infergen
ViraferonPeg
- PEGylated
- Approved EU since 2000
- Differs by presence of covalently attached PEG
- Schering Plough
- Treats chronic hepatitis C
- Displays prolonged half-life compared to non-PEG
(13-25 hours compared to 4 hours)